Skip to main content
SRZN
NASDAQ Life Sciences

10% Owner TCG Crossover Funds Increase Stake in Surrozen with $1.22M Open Market Purchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$25.5
Mkt Cap
$218.571M
52W Low
$5.9
52W High
$29.595
52W Position info
332% above low
Off High info
14% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

SRZN has more than doubled off its 52-week low of $5.9 on light trading volume (0.3× avg).

Summary

TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., along with their general partners, collectively increased their holdings in Surrozen, Inc. through open market purchases totaling over $1.22 million.


Key Events · Ownership and Investor Activity · SRZN

  • Significant Insider Purchase

    TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., both 10% owners, collectively purchased 48,997 shares of Surrozen, Inc. common stock.

  • Substantial Investment

    The open market purchases totaled $1,220,362, executed across six transactions between March 12 and March 16, 2026, at prices ranging from $24.88 to $24.99 per share.

  • Continued Accumulation

    This transaction adds to a pattern of insider accumulation, with net insider buys totaling $647,379 in the 90 days prior to this filing, indicating ongoing investor confidence.


Analysis · SRZN · Life Sciences

This Form 4 filing indicates a significant vote of confidence from a major institutional investor. TCG Crossover Funds, identified as 10% owners, acquired over $1.22 million worth of Surrozen common stock through multiple open market transactions between March 12 and March 16, 2026. While 10% owners are financial investors rather than operational insiders, such a substantial purchase suggests a positive outlook on the company's prospects and could be interpreted as a bullish signal for other investors. This purchase contributes to a broader pattern of insider accumulation observed over the last 90 days.

At the time of this filing, SRZN was trading at $25.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.6M. The 52-week trading range was $5.90 to $29.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRZN - Latest Insights

SRZN
May 18, 2026, 6:49 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $28.15
Real-time Price: $19.73 info
Change: -$8.42 (-30%) info
Market Cap: $229.073M info
SRZN
May 06, 2026, 4:49 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $34.13
Real-time Price: $19.73 info
Change: -$14.40 (-42%) info
Market Cap: $229.073M info
SRZN
May 06, 2026, 4:38 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $34.13
Real-time Price: $19.73 info
Change: -$14.40 (-42%) info
Market Cap: $229.073M info
SRZN
Mar 30, 2026, 6:21 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $27.45
Real-time Price: $19.73 info
Change: -$7.72 (-28%) info
Market Cap: $229.073M info
SRZN
Mar 25, 2026, 8:02 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $26.14
Real-time Price: $19.73 info
Change: -$6.41 (-25%) info
Market Cap: $229.073M info